Charles Schwab Investment Management Inc. Boosts Position in Regeneron Pharmaceuticals, Inc. $REGN

Charles Schwab Investment Management Inc. lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.4% during the second quarter, HoldingsChannel reports. The institutional investor owned 720,273 shares of the biopharmaceutical company’s stock after purchasing an additional 9,938 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $378,143,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. Brighton Jones LLC lifted its stake in Regeneron Pharmaceuticals by 261.8% in the 4th quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after purchasing an additional 686 shares in the last quarter. AE Wealth Management LLC increased its holdings in shares of Regeneron Pharmaceuticals by 25.0% in the first quarter. AE Wealth Management LLC now owns 2,225 shares of the biopharmaceutical company’s stock worth $1,412,000 after purchasing an additional 445 shares during the period. Avantax Advisory Services Inc. raised its position in shares of Regeneron Pharmaceuticals by 12.0% in the first quarter. Avantax Advisory Services Inc. now owns 1,819 shares of the biopharmaceutical company’s stock worth $1,154,000 after buying an additional 195 shares in the last quarter. Cetera Investment Advisers boosted its stake in Regeneron Pharmaceuticals by 14.5% during the first quarter. Cetera Investment Advisers now owns 10,575 shares of the biopharmaceutical company’s stock valued at $6,707,000 after buying an additional 1,336 shares during the period. Finally, LPL Financial LLC grew its position in Regeneron Pharmaceuticals by 1.4% during the first quarter. LPL Financial LLC now owns 55,245 shares of the biopharmaceutical company’s stock worth $35,038,000 after buying an additional 755 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Insider Activity at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Christine A. Poon sold 6,500 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total transaction of $4,252,755.00. Following the sale, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. The trade was a 73.43% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, VP Jason Pitofsky sold 431 shares of the company’s stock in a transaction dated Friday, November 7th. The stock was sold at an average price of $651.43, for a total transaction of $280,766.33. Following the completion of the sale, the vice president directly owned 4,233 shares in the company, valued at $2,757,503.19. This represents a 9.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 7.02% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the topic of several recent analyst reports. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $850.00 price target on shares of Regeneron Pharmaceuticals in a report on Thursday, October 23rd. Raymond James Financial raised shares of Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an “overweight” rating for the company in a research note on Friday, October 10th. Wells Fargo & Company raised their price objective on shares of Regeneron Pharmaceuticals from $615.00 to $700.00 and gave the company an “equal weight” rating in a research report on Thursday, November 20th. Finally, Sanford C. Bernstein upped their target price on shares of Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 27th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $757.91.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock opened at $761.45 on Tuesday. The company has a market capitalization of $80.03 billion, a P/E ratio of 18.23, a PEG ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $476.49 and a fifty-two week high of $800.99. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.72 and a current ratio of 4.06. The stock has a 50 day moving average price of $619.07 and a two-hundred day moving average price of $577.33.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. The company had revenue of $3.75 billion for the quarter, compared to the consensus estimate of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the previous year, the firm earned $12.46 earnings per share. Analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be issued a dividend of $0.88 per share. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date is Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio is currently 8.43%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.